Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro

Pharmacological Reports

Volumn 57, Issue 5, 2005, Pages 635-645

  Folwarczna, Joanna ^a   Śliwiński, Leszek ^a   Janiec, Waldemar ^a   Pikul, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Heparin; Low molecular weight heparins; Osteoclasts

Indexed keywords

CALCITRIOL; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL CULTURE; CELL GROWTH; CELL SIZE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GIANT CELL; IN VITRO STUDY; INHIBITION KINETICS; MOUSE; NEWBORN; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; RAT; SENSITIVITY ANALYSIS; SPECIES DIFFERENCE;

EID: 33646197779     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Backos M, Rai R, Thomas E, Murphy M, Doré C, Regan L: Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod, 1999, 14, 2876-2880.
2. Barbour LA, Kick SD, Steiner JF, LoVerde ME, Heddleston LN, Lear JL, Barón AE et al.: A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol, 1994, 170, 862-869.
3. Bhandari M, Hirsh J, Weitz JI, Young E, Venner TJ, Shaughnessy SG: The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost, 1998, 80, 413-417.
4. Blanquaert F, Barritault D, Caruelle J-P: Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression. J Biomed Mater Res, 1999, 44, 63-72.
5. Casele HL, Laifer SA: Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med, 2000, 9, 122-125.
6. Chowdhury MH, Hamada C, Dempster DW: Effects of heparin on osteoclast activity. J Bone Miner Res, 1992, 7, 771-777.
7. Eikelboom JW, Hankey GJ: Low molecular weight heparins and heparinoids. Med J Aust, 2002, 177, 379-383.
8. Erduran E, Tekelioglu Y, Gedik Y, Yildiran A: Apoptotic effects of heparin on lymphoblasts, neutrophils, and mononuclear cells: results of a preliminary in vitro study. Am J Hematol, 1999, 61, 90-93.
9. Folwarczna J, Janiec W, Barej M, Cegieła U, Pytlik M, Kaczmarczyk-Sedlak I: Effects of nadroparin on bone histomorphometric parameters in rats. Pol J Pharmacol, 2004, 56, 337-343.
10. Folwarczna J, Janiec W, Gawor M, Pytlik M, Kaczmarczyk-Sedlak I, Nowińska B: Effects of enoxaparin on histomorphometric parameters of bones in rats. Pol J Pharmacol, 2004, 56, 451-457.
11. Folwarczna J, Janiec W, Śliwiński L: Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats. Thromb Haemost, 2004, 92, 940-946.
12. Girasole G, Passeri G, Jilka RL, Manolagas SC: Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest, 1994, 93, 1516-1524.
13. Hausser HJ, Brenner RE: Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro. J Cell Biochem, 2004, 91, 1062-1073.
14. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C et al.: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 2001, 119, 1 Suppl, 64S-94S.
15. Karti SS, Ovali E, Ozgur O, Yilmaz M, Sonmez; M, Ratip S, Ozdemir F: Induction of apoptosis and inhibition of growth of human hepatoma HepG2 cells by heparin. Hepatogastroenterology, 2003, 50, 1864-1866.
16. Laurent P, Dussarat GV, Bonal J, Jego C, Talard P, Bouchiat C, Cellarier G: Low molecular weight heparins: a guide to their optimum use in pregnancy. Drugs, 2002, 62, 463-477.
17. Lenaers-Claeys G, Vaes G: Collagenase, procollagenase and bone resorption. Effects of heparin, parathyroid hormone and calcitonin. Biochim Biophys Acta, 1979, 584, 375-388.
18. Martineau P, Tawil N: Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother, 1998, 32, 588-598.
19. Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P: Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost, 1990, 63, 505-509.
20. Monreal M, Lafoz E, Olive A, delRio L, Vedia C: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost, 1994, 71, 7-11.
21. Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, Deschamps P, Shaughnessy SG: Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood, 1996, 88, 1314-1320.
22. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG: A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood, 1997, 89, 3236-3242.
23. Murray WJ, Lindo VS, Kakkar VV, Melissari E: Longterm administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coagul Fibrinolysis, 1995, 6, 113-118.
24. Mutoh S, Takeshita N, Yoshino T, Yamaguchi I: Characterization of heparin-induced osteopenia in rats. Endocrinology, 1993, 133, 2743-2748.
25. Nelson-Piercy C, Letsky EA, de Swiet M: Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol, 1997, 176, 1062-1068.
26. Nishiyama M, Itoh F, Ujiie A: Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Jpn J Pharmacol, 1997, 74, 59-68.
27. 3 or parathyroid hormone. J Biol Chem, 1999, 274, 19301-19308.
28. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R: Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost, 2002, 87, 182-186.
29. Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ et al.: The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med, 1996, 183, 2581-2591.
30. Shaughnessy SG, Hirsh J, Bhandari M, Muir JM, Young E, Weitz JI: A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood, 1999, 93, 1231-1236.
31. Shaughnessy SG, Young E, Deschamps P, Hirsh J: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood, 1995, 86, 1368-1373.
32. Shefras J, Farquharson RG: Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol, 1996, 65, 171-174.
33. Takahashi N, Udagawa N, Tanaka S, Suda T: Generating murine osteoclasts from bone marrow. In: Methods in Molecular Medicine. Ed. Helfrich MH, Ralston SH, Vol. 80, Bone Research Protocols, Humana Press, Totowa, NJ, 2003, 129-144.
34. Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G, Agnusdei D et al.: The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone, 2002, 30, 368-376.
35. Teti A, Taranta A, Villanova I, Recchia I, Migliaccio S: Osteoclast isolation: new developments and methods. J Bone Miner Res, 1999, 14, 1251-1252.
36. Walenga JM, Bick RL: Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am, 1998, 82, 635-658.
37. Walton KJ, Duncan JM, Deschamps P, Shaughnessy SG: Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood, 2002, 100, 2530-2536.
38. Wawrzyńska. L, Tomkowski WZ, Przedlacki J, Hajduk B, Torbicki A: Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb, 2003, 33, 64-67.
39. Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM: Osteoclast apoptosis: the role of Fas in vivo and in vitro. Endocrinology, 2003, 144, 5545-5555.